{"contentid": 488068, "importid": NaN, "name": "Expanded Keytruda indication in EU and first for pediatric patients", "introduction": "The European Commission (EC) has approved an expanded label for Keytruda (pembrolizumab) as monotherapy for adults and children aged three years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.", "content": "<p>The European Commission (EC) has approved an expanded label for Keytruda (pembrolizumab) as monotherapy for adults and children aged three years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.</p>\n<p>Merck &amp; Co&rsquo;s (NYSE: MRK) anti-PD-1 therapy won the approval partly based on results from the pivotal Phase III KEYNOTE-204 trial, in which Keytruda monotherapy demonstrated a significant improvement in progression-free survival (PFS) compared with brentuximab vedotin.</p>\n<p><span class=\"pullQuote\">\"The EC&rsquo;s approval of an expanded use of Keytruda provides another option for adult and pediatric patients with cHL who have disease progression after earlier lines of therapy or relapse after transplantation\"</span>Keytruda reduced the risk of disease progression or death by 35% and showed a median PFS of 13.2 months versus 8.3 months for patients treated with brentuximab vedotin, which is marketed by Takeda (TYO: 4502) and Seattle Genetics (Nasdaq: SGEN) as Adcetris.</p>\n<p>This marks the first pediatric approval for Keytruda in the European Union and means that it can be marketed in all 27 member states as well as Iceland, Lichtenstein, Norway and Northern Ireland.</p>\n<p>Vicki Goodman, vice president, clinical research, Merck Research Laboratories, said: &ldquo;The EC&rsquo;s approval of an expanded use of Keytruda provides another option for adult and pediatric patients with cHL who have disease progression after earlier lines of therapy or relapse after transplantation.</p>\n<p>&ldquo;We are driven to advance therapies to help improve outcomes for patients with blood cancers, including those with relapsed or refractory cHL, through our broad clinical program.&rdquo;</p>\n<p>&nbsp;</p>", "date": "2021-03-17 15:07:00", "meta_title": NaN, "meta_keywords": "Keytruda, expanded, patients, ASCT, pediatric, option, approval, monotherapy, European, relapsed, therapies, refractory, therapy, indication, disease, year", "meta_description": "The European Commission (EC) has approved an expanded label for Keytruda (pembrolizumab) as monotherapy for adults and children aged three years and older with ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-17 15:04:22", "updated": "2021-03-17 16:14:13", "access": NaN, "url": "https://www.thepharmaletter.com/article/expanded-keytruda-indication-in-eu-and-first-for-pediatric-patients", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "keytruda_merck_large.jpg", "image2id": "keytruda_merck_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "European Commission", "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Immuno-oncology, Oncology", "topic_tag": "European Medicines Agency, Focus On, Regulation", "geography_tag": "Europe, USA", "company_tag": "Merck & Co", "drug_tag": "Keytruda", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-17 15:07:00"}